Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leah Samuel

Senior Writer

Based in Boston, Leah was most recently with the Boston Globe’s STAT news publication – where she reported on biomedical research as well as general interest issues, like the growing phenomenon of people taking Uber to the ER and diversity in medical schools. She has decades of experience with investigative reporting and award-winning features writing, and has embraced the chance to take a deeper dive into the biopharma industry.
Set Alert for Articles By Leah Samuel

Latest From Leah Samuel

VBI Is Ready To Take On HBV Vaccine Market

VBI’s Sci-B-Vac CONSTANT data firmly establishes the hepatitis B vaccine’s advantages over GSK’s longstanding Engerix-B, but it faces a tougher challenge with Heplisav-B from Dynavax. 

Apellis Comes Closer To Taking On Alexion In PNH

Besting Alexion’s Soliris in a head-to-head Phase III trial portends a place in the market for Apellis’ competitor in paroxysmal nocturnal hemoglobinuria. But challenges dog both companies.

Research & Development Clinical Trials

Iterum Anxiously Awaiting Other Results After SURE 3 Failure

Iterum’s antibiotic sulopenem missed its endpoint by the equivalent of one patient. The company believes the Phase III data could still support its NDA for urinary tract infections.

Gynecology & Urology Infectious Diseases

Fledgling Pharma FerGene Makes Quick Debut With Gene Therapy Candidate

FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.

Clinical Trials Gene Therapy

Sage Still Sees Approval Path After Depression Drug Fails In Phase III Trial

Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies. 

Clinical Trials Neurology

Evofem Takes Aim At Preventing Pregnancy And STIs With Amphora

Evofem Biosciences is preparing for Phase III trials for Amphora, an on-demand contraceptive that has surpassed Phase II endpoints in preventing bacterial sexually transmitted infections. 

Clinical Trials Infectious Diseases
See All
UsernamePublicRestriction

Register